Influence of the Endoscopists and Endoscopic Retrograde CholangioPanceratography
NCT ID: NCT04705740
Last Updated: 2021-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2561 participants
OBSERVATIONAL
2020-09-01
2020-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography
NCT06670547
a Prediction of Post-Endoscopic Retrograde Cholangiopancreatography Complication
NCT06277414
Optimizing the Evaluation and Management of Patients With Suspected Choledocholithiasis
NCT05141916
Influence of Vater's Ampulla Morphology on ERCP
NCT04492124
Endoscopic Retrograde Cholangiopancreatography (ERCP) Based Sampling of Indeterminate Bile Duct Strictures
NCT01580709
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The hypothesis of this study is that the number of endoscopists who perform ERCP in a hospital influences the results of the procedure, so that the fewer the number of endoscopists the better the results.
To evaluate this hypothesis, the investigators have designed a retrospective study analyzing data from a prospectively filled database, which includes all ERCPs performed in our center from September 2013 to June 2020. For organizative reasons unrelated to the endoscopy unit, in the center it has beed progressively reduced the number of endoscopists who perform ERCP, starting from 5 endoscopists at the beginning of the study to 3 endoscopists at the end of the study inclusion period. In fact, three different periods of similar duration can be distinguished: September 2013 to August 2015 (5 endoscopists), September 2015 to December 2017 (4 endoscopists) and January 2018 to June 2020 (3 endoscopists).
The outcomes obtained with ERCP in these three periods will be analyzed and compared, assessing the cannulation rate and the adverse effects rate as the main comparison parameters.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
September 2013 to August 2015
5 endoscopists
ERCP
ERCPs performed annually by an endoscopist
September 2015 to December 2017
4 endoscopists
ERCP
ERCPs performed annually by an endoscopist
January 2018 to June 2020
3 endoscopists
ERCP
ERCPs performed annually by an endoscopist
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ERCP
ERCPs performed annually by an endoscopist
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Staff allocated in the endoscopy unit
Exclusion Criteria
* ERCP procedures performed by fellows in training
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Complejo Hospitalario de Navarra
OTHER
Fundacion Miguel Servet
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juan J Vila, PhD
Role: PRINCIPAL_INVESTIGATOR
Complejo Hospitalario de Navarra
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Complejo Hospitalario de Navarra
Pamplona, Navarre, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NER20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.